Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis

C. Maguire, H. Cantrill, D. Hind, M. Bradburn, Mark Everard

    Research output: Contribution to journalArticle

    34 Citations (Scopus)

    Abstract

    © 2015 Maguire et al. Background: Acute bronchiolitis is the commonest cause of hospitalisation in infancy. Currently management consists of supportive care and oxygen. A Cochrane review concluded that, nebulised 3% saline may significantly reduce the length of hospital stay. We conducted a systematic review of controlled trials of nebulised hypertonic saline (HS) for infants hospitalised with primary acute bronchiolitis. Methods: Searches to January 2015 involved: Cochrane Central Register of Controlled Trials; Ovid MEDLINE; Embase; Google Scholar; Web of Science; and, a variety of trials registers. We hand searched Chest, Paediatrics and Journal of Paediatrics on 14 January 2015. Reference lists of eligible trial publications were checked. Randomised or quasi-randomised trials which compared HS versus either normal saline (+/- adjunct treatment) or no treatment were included. Eligible studies involved children less than 2years old hospitalised due to the first episode of acute bronchiolitis. Two reviewers extracted data to calculate mean differences (MD) and 95% Confidence Intervals (CIs) for length of hospital stay (LoS-primary outcome), Clinical Severity Score (CSS) and Serious Adverse Events (SAEs). Meta-analysis was undertaken using a fixed effect model, supplemented with additional sensitivity analyses. We investigated statistical heterogeneity using I2. Risk of bias, within and between studies, was assessed using the Cochrane tool, an outcome reporting bias checklist and a funnel plot. Results: Fifteen trials were included in the systematic review (n=1922), HS reduced mean LoS by 0.36, (95% CI 0.50 to 0.22) days, but with considerable heterogeneity (I2=78%) and sensitivity to alternative analysis methods. A reduction in CSS was observed where assessed [n=516; MD -1.36, CI -1.52, -1.20]. One trial reported one possible intervention related SAE, no other studies described intervention related SAEs. Conclusions: There is disparity between the overall combined effect on LoS as compared with the negative results from the largest and most precise trials. Together with high levels of heterogeneity, this means that neither individual trials nor pooled estimates provide a firm evidence-base for routine use of HS in inpatient acute bronchiolitis.
    Original languageEnglish
    Pages (from-to)Article 148
    JournalBMC Pulmonary Medicine
    Volume15
    Issue number1
    DOIs
    Publication statusPublished - 2015

    Fingerprint

    Bronchiolitis
    Meta-Analysis
    Length of Stay
    Confidence Intervals
    Pediatrics
    Checklist
    MEDLINE
    Publications
    Inpatients
    Hospitalization
    Thorax
    Oxygen
    Therapeutics

    Cite this

    Maguire, C. ; Cantrill, H. ; Hind, D. ; Bradburn, M. ; Everard, Mark. / Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis. In: BMC Pulmonary Medicine. 2015 ; Vol. 15, No. 1. pp. Article 148.
    @article{5e363c8135d24fd3aa9f4281b9305ab6,
    title = "Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis",
    abstract = "{\circledC} 2015 Maguire et al. Background: Acute bronchiolitis is the commonest cause of hospitalisation in infancy. Currently management consists of supportive care and oxygen. A Cochrane review concluded that, nebulised 3{\%} saline may significantly reduce the length of hospital stay. We conducted a systematic review of controlled trials of nebulised hypertonic saline (HS) for infants hospitalised with primary acute bronchiolitis. Methods: Searches to January 2015 involved: Cochrane Central Register of Controlled Trials; Ovid MEDLINE; Embase; Google Scholar; Web of Science; and, a variety of trials registers. We hand searched Chest, Paediatrics and Journal of Paediatrics on 14 January 2015. Reference lists of eligible trial publications were checked. Randomised or quasi-randomised trials which compared HS versus either normal saline (+/- adjunct treatment) or no treatment were included. Eligible studies involved children less than 2years old hospitalised due to the first episode of acute bronchiolitis. Two reviewers extracted data to calculate mean differences (MD) and 95{\%} Confidence Intervals (CIs) for length of hospital stay (LoS-primary outcome), Clinical Severity Score (CSS) and Serious Adverse Events (SAEs). Meta-analysis was undertaken using a fixed effect model, supplemented with additional sensitivity analyses. We investigated statistical heterogeneity using I2. Risk of bias, within and between studies, was assessed using the Cochrane tool, an outcome reporting bias checklist and a funnel plot. Results: Fifteen trials were included in the systematic review (n=1922), HS reduced mean LoS by 0.36, (95{\%} CI 0.50 to 0.22) days, but with considerable heterogeneity (I2=78{\%}) and sensitivity to alternative analysis methods. A reduction in CSS was observed where assessed [n=516; MD -1.36, CI -1.52, -1.20]. One trial reported one possible intervention related SAE, no other studies described intervention related SAEs. Conclusions: There is disparity between the overall combined effect on LoS as compared with the negative results from the largest and most precise trials. Together with high levels of heterogeneity, this means that neither individual trials nor pooled estimates provide a firm evidence-base for routine use of HS in inpatient acute bronchiolitis.",
    author = "C. Maguire and H. Cantrill and D. Hind and M. Bradburn and Mark Everard",
    year = "2015",
    doi = "10.1186/s12890-015-0140-x",
    language = "English",
    volume = "15",
    pages = "Article 148",
    journal = "B M C Pulmonary Medicine",
    issn = "1471-2466",
    publisher = "BioMed Central",
    number = "1",

    }

    Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis. / Maguire, C.; Cantrill, H.; Hind, D.; Bradburn, M.; Everard, Mark.

    In: BMC Pulmonary Medicine, Vol. 15, No. 1, 2015, p. Article 148.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis

    AU - Maguire, C.

    AU - Cantrill, H.

    AU - Hind, D.

    AU - Bradburn, M.

    AU - Everard, Mark

    PY - 2015

    Y1 - 2015

    N2 - © 2015 Maguire et al. Background: Acute bronchiolitis is the commonest cause of hospitalisation in infancy. Currently management consists of supportive care and oxygen. A Cochrane review concluded that, nebulised 3% saline may significantly reduce the length of hospital stay. We conducted a systematic review of controlled trials of nebulised hypertonic saline (HS) for infants hospitalised with primary acute bronchiolitis. Methods: Searches to January 2015 involved: Cochrane Central Register of Controlled Trials; Ovid MEDLINE; Embase; Google Scholar; Web of Science; and, a variety of trials registers. We hand searched Chest, Paediatrics and Journal of Paediatrics on 14 January 2015. Reference lists of eligible trial publications were checked. Randomised or quasi-randomised trials which compared HS versus either normal saline (+/- adjunct treatment) or no treatment were included. Eligible studies involved children less than 2years old hospitalised due to the first episode of acute bronchiolitis. Two reviewers extracted data to calculate mean differences (MD) and 95% Confidence Intervals (CIs) for length of hospital stay (LoS-primary outcome), Clinical Severity Score (CSS) and Serious Adverse Events (SAEs). Meta-analysis was undertaken using a fixed effect model, supplemented with additional sensitivity analyses. We investigated statistical heterogeneity using I2. Risk of bias, within and between studies, was assessed using the Cochrane tool, an outcome reporting bias checklist and a funnel plot. Results: Fifteen trials were included in the systematic review (n=1922), HS reduced mean LoS by 0.36, (95% CI 0.50 to 0.22) days, but with considerable heterogeneity (I2=78%) and sensitivity to alternative analysis methods. A reduction in CSS was observed where assessed [n=516; MD -1.36, CI -1.52, -1.20]. One trial reported one possible intervention related SAE, no other studies described intervention related SAEs. Conclusions: There is disparity between the overall combined effect on LoS as compared with the negative results from the largest and most precise trials. Together with high levels of heterogeneity, this means that neither individual trials nor pooled estimates provide a firm evidence-base for routine use of HS in inpatient acute bronchiolitis.

    AB - © 2015 Maguire et al. Background: Acute bronchiolitis is the commonest cause of hospitalisation in infancy. Currently management consists of supportive care and oxygen. A Cochrane review concluded that, nebulised 3% saline may significantly reduce the length of hospital stay. We conducted a systematic review of controlled trials of nebulised hypertonic saline (HS) for infants hospitalised with primary acute bronchiolitis. Methods: Searches to January 2015 involved: Cochrane Central Register of Controlled Trials; Ovid MEDLINE; Embase; Google Scholar; Web of Science; and, a variety of trials registers. We hand searched Chest, Paediatrics and Journal of Paediatrics on 14 January 2015. Reference lists of eligible trial publications were checked. Randomised or quasi-randomised trials which compared HS versus either normal saline (+/- adjunct treatment) or no treatment were included. Eligible studies involved children less than 2years old hospitalised due to the first episode of acute bronchiolitis. Two reviewers extracted data to calculate mean differences (MD) and 95% Confidence Intervals (CIs) for length of hospital stay (LoS-primary outcome), Clinical Severity Score (CSS) and Serious Adverse Events (SAEs). Meta-analysis was undertaken using a fixed effect model, supplemented with additional sensitivity analyses. We investigated statistical heterogeneity using I2. Risk of bias, within and between studies, was assessed using the Cochrane tool, an outcome reporting bias checklist and a funnel plot. Results: Fifteen trials were included in the systematic review (n=1922), HS reduced mean LoS by 0.36, (95% CI 0.50 to 0.22) days, but with considerable heterogeneity (I2=78%) and sensitivity to alternative analysis methods. A reduction in CSS was observed where assessed [n=516; MD -1.36, CI -1.52, -1.20]. One trial reported one possible intervention related SAE, no other studies described intervention related SAEs. Conclusions: There is disparity between the overall combined effect on LoS as compared with the negative results from the largest and most precise trials. Together with high levels of heterogeneity, this means that neither individual trials nor pooled estimates provide a firm evidence-base for routine use of HS in inpatient acute bronchiolitis.

    U2 - 10.1186/s12890-015-0140-x

    DO - 10.1186/s12890-015-0140-x

    M3 - Article

    VL - 15

    SP - Article 148

    JO - B M C Pulmonary Medicine

    JF - B M C Pulmonary Medicine

    SN - 1471-2466

    IS - 1

    ER -